RhumbLine Advisers’s Purple Biotech PPBT Stock Holding History

RhumbLine Advisers’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.87K	Sell	710 -29	-4%	-$157	﹤0.01%	3913
2025 Q4	$4.86K	Buy	739 +631	+584%	+$4.58K	﹤0.01%	3926
2025 Q3	$614	Hold	108	–	–	﹤0.01%	4052
2025 Q2	$2.55K	Buy	108 +27	+33%	+$667	﹤0.01%	3974
2025 Q1	$2.19K	Buy	81 +20	+33%	+$639	﹤0.01%	3982
2024 Q4	$2.84K	Buy	+61	New	+$2.35K	﹤0.01%	4010
2024 Q3	–	Hold	0	–	-$6	–	4302
2024 Q2	–	Hold	0	–	–	–	4364
2024 Q1	–	Sell	-3	Closed	-$430	–	4248
2023 Q4	$432	Hold	3	–	–	﹤0.01%	4205
2023 Q3	$638	Hold	3	–	–	﹤0.01%	4217
2023 Q2	$777	Buy	+3	New	+$1.08K	﹤0.01%	4296

Other funds holding PPBT

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $240M AUM

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

RhumbLine Advisers's PPBT Position: Q1 2026 in Review

RhumbLine Advisers reduced its Purple Biotech (PPBT) stake by 3.9% in Q1 2026, selling an estimated $157 and leaving 710 shares worth $2.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3913.

RhumbLine Advisers first reported a position in PPBT in Q2 2023 and has held it in 9 quarters since. The position peaked at $4.86K in Q4 2025. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2026.

RhumbLine Advisers held 710 shares of Purple Biotech worth $2.87K as of Q1 2026.
RhumbLine Advisers sold 29 Purple Biotech shares in Q1 2026, an estimated $157.
Purple Biotech made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3913 holding.
RhumbLine Advisers first reported a position in Purple Biotech in Q2 2023 and has held it in 9 quarters since.
RhumbLine Advisers's Purple Biotech position peaked at $4.86K in Q4 2025.
15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.